DSIP

Delta Sleep-Inducing Peptide (DSIP) is a nine-amino-acid neuropeptide first identified in 1977 from rabbit brains and named for its ability to promote deep, slow-wave sleep Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives. Found naturally in the brain and cerebrospinal fluid, DSIP does not act like a simple on/off switch but instead fine-tunes the central nervous system, influencing sleep architecture, stress hormone release, seizure susceptibility, and pain perception Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives+1.

Since its discovery, research has explored DSIP for conditions ranging from insomnia and circadian disruption to neuroprotection after stroke, but the evidence base remains predominantly animal and mechanistic, with only a handful of older human sleep studies Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives+1. The peptide breaks down rapidly in the body—its half-life is measured in minutes—which has made it difficult to develop as a practical therapeutic. Most current use is in experimental settings or community protocols, where it is taken as a short-acting sleep aid rather than a proven medication Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives.

DSIP doesn't target a single receptor. Instead, research points to a multisite neuromodulator role: it dials up inhibitory (GABAergic) and dials down excitatory (glutamatergic/NMDA) signaling in the brain Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives+1. This shift can promote sleep onset, reduce seizure activity, and lower the body's stress response by blunting the release of corticotropin-releasing hormone (CRH) and cortisol Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives+1.

Some studies also show that DSIP enhances nighttime growth hormone pulses, which may contribute to its reputation as a recovery peptide Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives. The peptide is rapidly degraded by peptidase enzymes in cerebrospinal fluid and blood, so its effects are short-lived—minutes rather than hours Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives. Newer engineered fusion peptides are being tested to improve brain penetration and extend duration Pichia pastoris secreted peptides crossing the blood-brain barrier and DSIP fusion peptide efficacy in PCPA-induced insomnia mouse models+1.

Sleep – Older human trials using intravenous DSIP (25 nmol/kg) reported improved sleep efficiency and reduced awakenings in chronic insomniacs, though the studies were small and short-term Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions+1. Animal research with blood-brain-barrier-penetrating DSIP analogs also normalized sleep-related neurotransmitter imbalances Pichia pastoris secreted peptides crossing the blood-brain barrier and DSIP fusion peptide efficacy in PCPA-induced insomnia mouse models.

Stress and hormones – DSIP can reduce cortisol output in response to stress and increase nocturnal growth hormone pulses in animals and limited human samples Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives+1.

Seizures and neuroprotection – Preclinical models show anticonvulsant effects and reduced seizure severity Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives+1. In stroke rats, intranasal DSIP accelerated recovery of motor function without shrinking the infarct, suggesting functional benefit Delta Sleep-Inducing Peptide Recovers Motor Function in SD Rats after Focal Stroke.

Pain – Animal hot-plate tests show increased pain thresholds, though the pathway is inconsistent—sometimes blocked by naloxone, sometimes not Peptide-Based Approaches for Pain Relief and Healing in Wounds.

All of these findings come from preclinical work or historical small-scale human studies; no modern large trial has replicated the results.

Published human dosing protocols are limited to a few intravenous studies. In those trials, 25 nanomoles per kilogram (nmol/kg)—roughly 20–21 micrograms per kilogram (mcg/kg)—was given daily for 3–7 days Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions+1 (historical human data). Because DSIP is rapidly broken down, researchers today typically use subcutaneous or intramuscular injections to slow absorption and extend the effect window.

Common community research protocols begin at 100–300 mcg taken once nightly, about 30–60 minutes before bed. Doses are sometimes titrated up to 500 mcg if lower doses are well tolerated but insufficient Isoaspartate formation and irreversible aggregation of collapsin response mediator protein 2: implications for the etiology of epilepsy and age-related cognitive decline[community protocol]. Weight-based dosing often starts at 1.5–3 mcg/kg and may increase to 4–6 mcg/kg [community protocol]. Cycles usually last 2–6 weeks, followed by a break, as there is no evidence supporting indefinite daily use.

DSIP is highly susceptible to enzymatic degradation, so careful handling is essential. Lyophilized powder should be stored at -20°C and protected from moisture Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives. For reconstitution, most protocols use bacteriostatic water to allow multi-dose use, adding the diluent slowly down the vial wall and swirling gently [community protocol].

Once mixed, the solution should be kept refrigerated at 2–8°C and used within 2–4 weeks to minimize degradation. For longer storage, divide the solution into sterile single-use aliquots and freeze at -20°C, avoiding repeated freeze-thaw cycles Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives+1. An interactive calculator on this page can help determine exact concentrations and dosing volumes based on your vial size.

No formal human interaction studies exist for DSIP. Based on its sedative and blood-pressure-lowering effects, researchers should be cautious when combining it with:

• Sedatives/hypnotics, alcohol, opioids – Additive drowsiness and next-day impairment are likely Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives.
• Antihypertensives – DSIP can cause mild dips in blood pressure, so orthostasis may increase Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives.
• Growth hormone secretagogues (CJC-1295, ipamorelin, etc.) – May amplify nighttime growth hormone pulses, but evidence is weak Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives.
• Other CNS-active peptides (Selank, Semax) – Mechanistically complementary but unpredictable Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives.

Because DSIP is rapidly cleared, interactions are likely acute and wear off quickly. Still, any stack with other sedating substances raises the risk of oversedation.

Research does not directly prove that DSIP causes tolerance, but due to its very short half-life and the lack of chronic human data, cycling is a common empirical strategy. Popular patterns include:

• 5 nights on, 2 nights off – Used for weekly sleep support [community protocol].
• 2–4 weeks on, 1–2 weeks off – Allows assessment of effect and minimizes the unknown risks of continuous use [community protocol].
• As-needed use (1–4 nights per week) – For situational sleep disruption, such as travel [community protocol].

A common research approach is to run a 2–4 week cycle, evaluate sleep and daytime function, then take a break of equal or longer length.

DSIP is often stacked with other peptides in community protocols, though evidence of synergy is minimal. Reported pairings include:

• GHRH/GHRP peptides (Ipamorelin, CJC-1295) – Intended to boost sleep-related growth hormone; theoretical but unproven Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives.
• Semax/Selank – Combined for daytime cognitive support with nighttime sleep recovery; mechanistically plausible Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives.
• BPC-157/TB-500 – For injury recovery, with DSIP added for sleep quality Decreased Delta-Sleep and Plasma Delta-Sleep-Inducing Peptide in Patients with Cushing Syndrome.

Adding DSIP to a stable regimen is typically done one compound at a time to isolate effects. Overstacking multiple untested peptides in a single cycle increases the risk of adverse effects and makes it impossible to attribute changes to any one agent.

DSIP is not an FDA-approved drug in the United States or any major Western regulatory agency Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives. It is sold as a research peptide and is not legally permitted for human consumption or therapeutic use. The World Anti-Doping Agency (WADA) lists DSIP under category S2 (Peptide Hormones, Growth Factors, and Related Substances), meaning it is prohibited for athletes at all times Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives.

There is no evidence that DSIP is scheduled by the DEA, but its unapproved status places it in a legal gray area; possession and purchase for research purposes may be subject to varying enforcement depending on jurisdiction. International status mirrors the US, with no country explicitly approving DSIP as a medicine.

DSIP appears relatively well tolerated in the limited data available. The most commonly reported side effects are excessive sleepiness, next-day grogginess, and mild drops in blood pressure during rapid infusion Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives. Community reports also mention vivid dreams and morning headache [community protocol].

Contraindications

• Absolute: Prior hypersensitivity to DSIP, unstable hypotension, or inability to avoid hazardous activities after dosing Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives.
• Relative: Combination with alcohol, sedatives, or opioids; untreated sleep apnea; seizure disorders; and endocrine conditions affecting cortisol or growth hormone Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives+1.

What We Don't Know

Long-term safety has not been studied in humans. Risks of chronic use, hormonal suppression, or interactions with common medications remain unknown. Use in pregnancy, breastfeeding, or children is not appropriate given the complete absence of data.